Floatz logo

Anetumab Ravtansine

Ovarian Endometrioid Adenocarcinoma

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

43 Active assets in the Ovarian Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Genelux Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Anetumab Ravtansine is also rated in:

fallopian tube endometrioid adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
ovarian serous adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →